Korean J Med.  2015 Jun;88(6):647-650. 10.3904/kjm.2015.88.6.647.

Treatment of Special Populations with Hepatitis C Virus Infection: Chronic Kidney Disease

• Chung WJ

• KMID: 2269071
• DOI: http://doi.org/10.3904/kjm.2015.88.6.647

Abstract

Hepatitis C virus (HCV) infection is prevalent in patients with chronic kidney disease, especially those on hemodialysis. Chronic HCV infection in patients with end-stage renal disease is associated with increased morbidity and mortality in the pre- and post-kidney transplant periods. Increased mortality is associated with liver complications and an elevated cardiovascular risk in HCV-infected patients on hemodialysis. Antiviral treatment may improve the prognosis of patients with HCV, and standard interferon remains the cornerstone of treatment. Direct-acting antiviral agents (DAA) are a potential new treatment modality for chronic HCV infection. Whatever DAA combination is administered, the use of ribavirin is still problematic in this population and this might affect the virological outcomes of some anti-HCV therapies.

Keyword

Hepatitis C; Renal insufficiency, Chronic; Renal dialysis

MeSH Terms

Antiviral Agents
Hepacivirus*
Hepatitis C
Humans
Interferons
Kidney Failure, Chronic
Liver
Mortality
Prognosis
Renal Dialysis
Renal Insufficiency, Chronic*
Ribavirin
Antiviral Agents
Interferons
Ribavirin